Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
AssigneeNuclea Biomarkers, LLC
InventorPatrick Muraca
Life of this patent
Estimating the term…
Abstract
The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample.
Claims10
A gene expression profile for determining if a patient is a responder to treatment with irinotecan comprising at least about four or more genes selected from the group consisting of:
- ERBB2, GRB7, Erk1 kinase, JNK1 kinase, BCL2, MK167, phospho-Akt, CD68, BAG1, phospho-GSK-3beta, MMP11, CTSL2, CCNB1, BIRC5, STK6, MRP14 and GSTM1.
A method of determining if a patient is a responder to treatment with irinotecan comprising:
- a. obtaining colon cancer tissue from at least one patient diagnosed with colon cancer;
- and
- b. determining the presence or absence in the sample of a gene expression profile wherein at least about four or more genes selected from the group consisting of:
- ERBB2, GRB7, JNK1 kinase, BCL2, MK167, phospho-Akt, CD68 and BAG1, are up-regulated and Erk1 kinase, phospho-GSK-3beta, MMP11, CTSL2, CCNB1, BIRC5, STK6, MRP14 and GSTM1 are down-regulated.
A method of determining if a patient is a responder to treatment with irinotecan comprising:
- a. obtaining colon cancer tissue from at least one patient diagnosed with colon cancer;
- and
- b. determining the presence or absence in the sample of a protein expression profile wherein at least about four or more proteins selected from the group consisting of:
- ERBB2, GRB7, JNK1 kinase, BCL2, MK167, phospho-Akt, CD68 and BAG1, are up-regulated and Erk1 kinase, phospho-GSK-3beta, MMP11, CTSL2, CCNB1, BIRC5, STK6, MRP14 and GSTM1 are down-regulated.
Dependencies are inferred from the claim text.